354795-62-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Methylisoxazol-4-amine is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with diverse therapeutic profiles. Its incorporation into drug molecules can enhance pharmacological activity and selectivity, leading to improved treatment options for various medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Methylisoxazol-4-amine serves as a precursor in the production of agrochemicals, such as pesticides and herbicides. Its chemical properties allow for the creation of effective compounds that can protect crops from pests and diseases, thereby contributing to increased agricultural productivity.
Used in Organic Chemistry:
3-Methylisoxazol-4-amine is utilized as a building block in organic chemistry for the preparation of various bioactive compounds. Its structural features make it a valuable component in the synthesis of complex organic substances, facilitating the development of novel chemical entities with potential applications in various fields.
Used in Medicinal Chemistry Research:
3-Methylisoxazol-4-amine is employed as a drug candidate in medicinal chemistry research due to its pharmacological properties. Its potential for therapeutic indications has made it a subject of investigation, with the aim of discovering new treatments for a range of diseases and conditions.

Upstream product

• 1122-05-0 3-methyl-4-nitroisoxazole 
• 1285517-11-4 tert-butyl (3-methylisoxazol-4-yl)carbamate 

Downstream Products

• 1362818-22-1 N-(3-methyl-4-isoxazolyl)-5-(1-methyl-1H-pyrazol-4-yl)-4-(4-morpholinylcarbonyl)-2-[(phenylmethyl)oxy]benzamide 
• 1362818-13-0 5-bromo-2-{[(2,4-difluorophenyl)methyl]oxy}-N-(3-methyl-4-isoxazolyl)-4-(4-morpholinylmethyl)benzamide 
• 1362818-03-8 5-bromo-2-{[(4-fluorophenyl)methyl]oxy}-N-(3-methyl-4-isoxazolyl)-4-(4-morpholinylmethyl)benzamide 
• 1362818-74-3 5-chloro-4-[(3,3-difluoro-1-pyrrolidinyl)carbonyl]-N-(3-methyl-4-isoxazolyl)-2-[(phenylmethyl)oxy]benzamide 
• 1285515-74-3 2-{[(4-fluorophenyl)methyl]oxy}-N-(3-methyl-4-isoxazolyl)-5-(trifluoromethyl)benzamide 
• 1285515-67-4 2-{[(4-fluorophenyl)methyl]oxy}-N-(3-methyl-4-isoxazolyl)-5-{1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl}benzamide 
• 1285514-41-1 N-(3-methyl-4-isoxazolyl)-2-[(phenylmethyl)oxy]-5-(4-pyridinyl)benzamide 

Relevant academic research and scientific papers

Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases

Autoreactive B cell-derived antibodies form immune complexes that likely play a pathogenic role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind Fc receptors on myeloid cells and induce proinflammatory cytokine producti

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

NOVEL COMPOUNDS

The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.

Synthesis of 4(5)-Acyl-, 1-Substituted 5-Acyl, and 1-Substituted 4-Acyl-1H-imidazoles from 4-Aminoisoxazoles

4-Aminoisoxazoles can be acylated with a wide variety of activated carboxylic acids.Hydrogenation of the resulting amides gives α-(acylamino)enaminones, which cyclize to 4(5)-acylimidazoles upon treatment with base.This method allows for the synthesis of acylimidazoles with a wide range of substituents at C-2.Utilization of N-substituted 4-aminoisoxazoles in the same sequence of reactions yields 1-substituted 5-acylimidazoles, a substitution pattern not otherwise easily prepared.Treatment of α-(acylamino)enaminones, derived from N-unsubstituted isoxazoles, with primary amines leads to incorporation of the amine at the β-position with concomitant expulsion of ammonia.This sequence efficiently yields 1-substituted and 1,2-disubstituted 4-acylimidazoles but does not give satisfactory yields of 5-substituted 4-acylimidazoles due to steric inhibition of the amine exchange.